What to Know About the New “Cancer Vaccine”

A treatment once regarded as closer to science fiction than legitimate medicine may be moving toward reality. Moderna and Merck announced last week that their experimental personalized cancer vaccine, known as intismeran autogene, or mRNA-4157, succeeded in a large Phase 3 trial of patients with high-risk melanoma.

According to a press release from Moderna, patients who received the vaccine along with Merck’s immunotherapy drug Keytruda went longer without their cancer returning or spreading than patients who received Keytruda alone.

The first thing to understand is that this is not a vaccine that prevents healthy people from getting melanoma. It is a treatment given after a dangerous melanoma has already been surgically removed. The goal is to train the immune system to find and destroy cancer cells too small to be seen or removed during surgery before they can grow into another tumor.

While not a true vaccine like the polio vaccine or measles vaccine, the National Cancer Institute calls this a “cancer treatment vaccine.”

The Phase 3 trial enrolled 1,137 patients with stage IIB through stage IV melanoma whose tumors had been completely removed. Patients received either Keytruda plus the personalized vaccine or Keytruda alone for roughly a year. Moderna and Merck said the combination produced “statistically significant and clinically meaningful” improvements in preventing both recurrence and distant metastasis.

In plain English, that means the cancer was less likely to come back or spread elsewhere in the body when patients had Keytruda plus mRNA-4157.

There is an important caveat here, however. Moderna and Merck have not yet released the actual numbers from the Phase 3 trial, and the findings have not yet been fully presented or peer reviewed. But an earlier Phase 2b trial involving 157 patients has now been followed for five years. In that earlier trial, adding the vaccine to Keytruda reduced the risk of recurrence or death by 49 percent and the risk of distant spread or death by 59 percent.

So, how does it work?

After surgeons remove a tumor, doctors compare genetic information from the cancer with healthy tissue. Cancer develops through mutations, and some mutations create abnormal proteins, called “neoantigens,” that appear on cancer cells but not normal ones. Those neoantigens act like a molecular fingerprint the immune system can use to identify the cancer.

That is where artificial intelligence comes in. Moderna uses AI-powered algorithms to sift through the mutations in a patient’s tumor and predict which neoantigens are most likely to trigger a strong immune response.

The system selects up to 34 targets, and Moderna manufactures an mRNA treatment specifically for that patient – like a personalized cancer drug. The vaccine then teaches immune cells what the cancer looks like and what to attack. Moderna has previously explained that AI is central to quickly sorting through this enormous amount of genetic information.

Dr. Murad Alam, chief of dermatology at Northwestern Medicine in Chicago, told Fox News that this degree of personalization would have been extraordinarily difficult without AI. “These things are difficult, and historically [they] took a lot of time, and it just wouldn’t be feasible to do this for every individual patient without the power of AI,” he said. “Here, AI is a tool that allows you in a reasonable amount of time, with a reasonable amount of resources ... to come up with a vaccine for that individual person.”

Keytruda provides another piece of the puzzle. Cancer can exploit natural “brakes” in the immune system that normally keep immune cells from attacking healthy tissue. Keytruda blocks one of those brakes, called PD-1, allowing immune cells to attack cancer more effectively.

Put simply, the vaccine teaches the immune system what to look for, while Keytruda helps give it permission to attack.

“For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational,” Moderna CEO Stéphane Bancel said. “We are now helping turn that vision into a reality.”

mRNA, short for “messenger RNA,” is essentially a temporary set of biological instructions that tells cells to make a specific protein. Unlike traditional vaccines, which often introduce a weakened virus or pieces of a pathogen, mRNA technology delivers instructions that prompt the body to produce a chosen target, allowing the immune system to learn to recognize it — an approach that can also be adapted to teach immune cells what a particular cancer looks like.

While legitimate concerns remain about mRNA technology – particularly following the rollout of the COVID-19 vaccine, which is an mRNA vaccine – researchers remain optimistic that this new frontier in medical research can cure cancers and diseases once thought incurable.

The AI component is particularly notable. While there are worries about how artificial intelligence could affect employment, privacy, fraud, misinformation, and other aspects of American life, this is a concrete example of how AI can perform a task that would be prohibitively slow and complex for humans alone.

Still, the results are not a reason for unbridled optimism just yet. Researchers still need to determine whether the treatment ultimately helps patients live longer, and the full Phase 3 efficacy and safety data is not yet out.

Personalized manufacturing is another challenge. Every treatment must be designed and manufactured for one patient. Nature reports that producing a personalized vaccine can take several months, a potential limitation for patients with rapidly progressing cancers.

The treatment is also not yet FDA-approved. Moderna and Merck say they plan to meet with regulators about potential filings, and Reuters reports that approval could potentially come as early as 2027. Analysts have likewise projected a commercial launch next year, but that remains a forecast rather than a firm company timetable. The FDA will first have to review the complete evidence on effectiveness and safety.

Perhaps the biggest question is whether the same approach will work against other cancers. The current Merck pipeline includes trials for non-small cell lung cancer, bladder cancer, and kidney cancer. Researchers are also investigating personalized cancer vaccines against other tumors. But melanoma may be especially well-suited to the technique because it often contains many mutations, giving the immune system more possible targets. Cancers with fewer recognizable mutations could prove more difficult.

Even with those caveats, the results mark a major milestone in cancer treatment. If the findings withstand full scientific scrutiny and regulators approve the vaccine, this could be not only a new chapter in melanoma care, but an early glimpse of a future in which doctors use AI and a patient’s own genetic information to build cancer treatments specifically for them.